One possibility is they buy up the Pitney arm of PAA in Sydney where MPL is being developed. Another possibility is some sort of long term rights with shared developement. Lots of permutations are possible. Just speculatiing, Elanco probably make an ideal partner for long term development, not only for access to the animal market, but as a development and financing platform from which to launch into the far larger and more lucrative human ocological market. It's good that there are people on the board who have experience in big pharma.
The ELANCO OPTION $ The Real Deals $, page-21
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.015(6.98%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 23.0¢ | 21.5¢ | $475.3K | 2.128M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 93524 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 71004 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable
